Please assess the completion status of the following clinical trial:

Trial Title: Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Currently treated with basal insulin once or twice daily with or without oral anti-diabetic drugs (OADs) for at least 3 months~* HbA1c (glycosylated haemoglobin A1c) within the range of 7.5% to10.0% ( both inclusive)~* BMI (Body Mass Index) maximum 40 kg/m2~Exclusion Criteria:~* Metformin contraindications according to local practice~* Systemically treated with TZDs (thiazolidinediones) for more than one month within 6 months prior to this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIAsp 30-30 (Type: EXPERIMENTAL): Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 1000-2000mg, up to three times daily

Based on this trial design, predict the completion outcome and termination type (if applicable).